Acute pancreatitis associated with lisinopril and olanzapine

February 2010
American Journal of Health-System Pharmacy;2/1/2010, Vol. 67 Issue 3, p214
Academic Journal
Case Study
Purpose. A case of acute pancreatitis associated with lisinopril and olanzapine is described. Summary. A 69-year-old woman came to the emergency department after four days of experiencing epigastric pressurelike pain that radiated to the left lower quadrant and worsened with ingestion of food. She had started lisinopril three months prior for treatment of hypertension and had been taking olanzapine regularly for bipolar disorder. Upon admission, she was afebrile and hemodynamically stable and exhibited tenderness of the epigastric region. Elevated pancreatic enzymes and abdominal computed tomography (CT) imaging findings confirmed the diagnosis of pancreatitis. Common causes of pancreatitis were ruled out, and it was determined that the recent combination of lisinopril and olanzapine was the likely cause. Food and liquids were withheld, and all oral medications were stopped at hospital admission. Her pain resolved completely after two days. She was discharged on hospital day 4, and all of her medications except lisinopril and olanzapine were resumed. During a follow-up visit with her primary care physician, she reported to be doing well and had no systemic complaints. Olanzapine was reinitiated at that time but was discontinued a month later by her psychiatrist, who was concerned about the development of recurrent symptoms of pancreatitis. Valsartan was prescribed to achieve optimal blood pressure control three weeks after discharge. A follow-up CT scan of the abdomen a month later found no residual pancreatic abnormalities. Conclusion. The additive effect of two known pancreatitis-causing medications resulted in increased risk and subsequent acute pancreatitis in this patient.


Related Articles

  • Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. Sawada, T; Takahashi, T; Yamada, H; Dahlöf, B; Matsubara, H // Journal of Human Hypertension;Sep2013, Vol. 27 Issue 9, p580 

    A correction to the article related to the effects of valsartan on morbidity and mortality in hypertensive patients that was published in the previous issue of the journal is presented.

  • Valsartan.  // Reactions Weekly;May2014, Vol. 1499 Issue 1, p32 

    An abstract of the article "Valsartan-induced acute pancreatitis," by B. Can and colleagues is presented.

  • Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. Kurata, M.; Okura, T.; Irita, J.; Enomoto, D.; Nagao, T.; Jotoku, M.; Miyoshi, K.; Desilva, V. R.; Higaki, J. // Journal of Human Hypertension;May2011, Vol. 25 Issue 5, p334 

    Osteopontin (OPN) has recently emerged as a key factor in both vascular remodelling and development of atherosclerosis. It has been reported that OPN is regulated by the renin-angiotensin-aldosterone system (RAAS). The aim of this study was to clarify the effect of angiotensin II receptor...

  • Dynaval Co Tablets.  // South African Family Practice;2014, Vol. 56 Issue 2, p86 

    The article evaluates the Dynaval Co (valsartan/hydrochlorothiazide) tablets for mild to moderate hypertension from Pharma Dynamics.

  • Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine. de Beaurepaire, Renaud; Honig, Adriaan; MacQueen, Glenda // Current Medical Literature: Psychiatry;2011, Vol. 22 Issue 2, p64 

    The article discusses a study on the effects of valsartan and telmisartan on insulin resistance and hyperinsulinemia in olanzapine-treated patients with schizophrenia. The study included 30 patients undergoing olanzapine for more than 8 weeks. It suggests that valsartan increases insulin...

  • Development and Validation of UV-Spectrophotometric methods for estimation of Valsartan in bulk and tablet dosage form. Tarkase Kailash, N.; Tajane Sachin, R.; Jadhav Manisha, B. // Journal of Pharmacy Research;2012, Vol. 5 Issue 4, p2344 

    Valsartan is an Angiotensin II receptor blocker drug used in hypertension and other cardiac diseases. Various methods for analysis of the same are available but are time consuming and expensive. Here we have developed two new, precise and simple UV spectrophotometric methods for estimation of...

  • New ARB Outperforms Older Agents.  // American Health & Drug Benefits;May/Jun2010, Vol. 3 Issue 3, p210 

    The article presents results from a study presented at the 2010 American Society of Hypertension (ASH) conference that compared the effectiveness of the angiotensin receptor blocker (ARB) azilsartan to olmesartan and valsartan in lowering blood pressure.

  • Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Miyagawa, Katsutosh; Kondo, Tatsuya; Goto, Rieko; Matsuyama, Rina; Ono, Kaoru; Kitano, Sayaka; Kawasaki, Shuji; Igata, Motoyuki; Kawashima, Junji; Matsumura, Takeshi; Motoshima, Hiroyuki; Araki, Eiichi // Cardiovascular Diabetology;2013, Vol. 12 Issue 1, p1 

    Background Dipeptidyl peptidase-4 (DPP-4) inhibitors modulate incretin hormones and exert anti-diabetic effects in type 2 diabetes mellitus. Treatment with angiotensin II type 1 receptor blockers (ARB) is a proven successful intervention for hypertension with type 2 diabetes. The present study...

  • JournalScan. Alistair, Lindsay // Heart;Jul2010, Vol. 96 Issue 13, p1078 

    The article discusses a research study on the efficacy of a novel dual-acting neprilysin and renin-angiotensin-aldosterone system (RAAS) inhibitor called LCZ696 in patients with mild-to-moderate hypertension. The effect of inhibition of neprilysin is cited. The study subjects were randomly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics